Matrix Trust Company’s Bristol-Myers Squibb BMY Stock Holding History

Matrix Trust Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21,793	Closed	-$1.18M	–	172
2024 Q1	$1.18M	Sell	21,793 -920	-4%	-$46.9K	0.27%	47
2023 Q4	$1.17M	Sell	22,713 -642	-3%	-$33.7K	0.27%	46
2023 Q3	$1.36M	Buy	23,355 +162	+0.7%	+$9.93K	0.35%	42
2023 Q2	$1.48M	Buy	+23,193	New	+$1.56M	0.38%	38

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Matrix Trust Company's BMY Position: Q2 2024 in Review

Matrix Trust Company sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 21,793 shares — an estimated $1.18M sold.

Matrix Trust Company first reported a position in BMY in Q2 2023 and held it in 4 quarters. The position peaked at $1.48M in Q2 2023. 2,153 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Matrix Trust Company reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Matrix Trust Company sold 21,793 Bristol-Myers Squibb shares in Q2 2024, an estimated $1.18M.
Matrix Trust Company first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 4 quarters.
Matrix Trust Company's Bristol-Myers Squibb position peaked at $1.48M in Q2 2023.
2,153 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Matrix Trust Company's 13F filing for Q2 2024, filed 10 Jul 2024.